Search Results - "Coiffier, B."

Rituximab therapy in malignant lymphoma by Coiffier, B

“…Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies have demonstrated its activity in…”
Get full text

Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte by FEUGIER, P, VAN HOOF, A, GAULARD, P, SALLES, G, BOSLY, A, GISSELBRECHT, C, REYES, F, COIFFIER, B, SEBBAN, C, SOLAL-CELIGNY, P, BOUABDALLAH, R, FERME, C, CHRISTIAN, B, LEPAGE, E, TILLY, H, MORSCHHAUSER, F

“…To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine,…”
Get full text

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) by Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J.F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A.D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T.E., Sehn, L.H., Engert, A., Fisher, R.I., Zinzani, P.-L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y.A., Tobinai, K., Abramson, J.S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R.F., Aurer, I., Van Oers, M.H.J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M.S., Meignan, M., Schwartz, L.H., Leonard, J.P., Schuster, S.J., Seshan, V.E.

“…In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged…”
Get full text

Diffuse large B-cell lymphoma (DLBCL), 2 versus 3: end of a debate? by Sarkozy, C., Coiffier, B.

Get full text

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials by Maurer, M.J., Habermann, T.M., Shi, Q., Schmitz, N., Cunningham, D., Pfreundschuh, M., Seymour, J.F., Jaeger, U., Haioun, C., Tilly, H., Ghesquieres, H., Merli, F., Ziepert, M., Herbrecht, R., Flament, J., Fu, T., Flowers, C.R., Coiffier, B.

“…Patients with diffuse large B-cell lymphoma treated with first-line anthracycline-based immunochemotherapy and remaining in remission at 2 years have excellent…”
Get full text

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis by Fleury, I., Chevret, S., Pfreundschuh, M., Salles, G., Coiffier, B., van Oers, M.H.J., Gisselbrecht, C., Zucca, E., Herold, M., Ghielmini, M., Thieblemont, C.

“…Addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy improves response rates and survival in patients with B-cell non-Hodgkin lymphoma…”
Get full text

Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome by Thieblemont, C., Grossoeuvre, A., Houot, R., Broussais-Guillaumont, F., Salles, G., Traullé, C., Espinouse, D., Coiffier, B.

“…Background: Non-Hodgkin’s lymphoma (NHL) in patients older than 80 years is not a rare disease and treatment strategies are often difficult because of…”
Get full text

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria by Matutes, E, Oscier, D, Montalban, C, Berger, F, Callet-Bauchu, E, Dogan, A, Felman, P, Franco, V, Iannitto, E, Mollejo, M, Papadaki, T, Remstein, E D, Salar, A, Solé, F, Stamatopoulos, K, Thieblemont, C, Traverse-Glehen, A, Wotherspoon, A, Coiffier, B, Piris, M A

“…Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL…”
Get full text

Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults by HEQUET, O, LE, Q. H, BOUAFIA, F, COIFFIER, B, MOULLET, I, PAULI, E, SALLES, G, ESPINOUSE, D, DUMONTET, C, THIEBLEMONT, C, ARNAUD, P, ANTAL, D

“…To assess the cardiac status of the long-term survivors and to estimate the incidence and the features of subclinical cardiotoxicity induced after conventional…”
Get full text

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma by Morschhauser, F., Marlton, P., Vitolo, U., Lindén, O., Seymour, J.F., Crump, M., Coiffier, B., Foà, R., Wassner, E., Burger, H.-U., Brennan, B., Mendila, M.

“…Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated…”
Get full text

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma by Crump, M., Coiffier, B., Jacobsen, E. D., Sun, L., Ricker, J. L., Xie, H., Frankel, S. R., Randolph, S. S., Cheson, B. D.

“…Background: Vorinostat has demonstrated activity in refractory cutaneous T-cell lymphoma. In a phase I trial, an encouraging activity in diffuse large-B-cell…”
Get full text

Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab by Lassau, N., Coiffier, B., Kind, M., Vilgrain, V., Lacroix, J., Cuinet, M., Taieb, S., Aziza, R., Sarran, A., Labbe-Devilliers, C., Gallix, B., Lucidarme, O., Ptak, Y., Rocher, L., Caquot, L.M., Chagnon, S., Marion, D., Luciani, A., Feutray, S., Uzan-Augui, J., Benatsou, B., Bonastre, J., Koscielny, S.

“…Dynamic contrast-enhanced ultrasonography (DCE-US) has been used for evaluation of tumor response to antiangiogenic treatments. The objective of this study was…”
Get full text

Impact of epoetin β on quality of life in patients with malignant disease by BOOGAERTS, M, COIFFIER, B, KAINZ, C

“…This open-label, prospective study was conducted to compare the impact of epoetin beta vs standard care on quality of life (QoL) in anaemic patients with…”
Get full text

Unmet needs in the scientific approach to older patients with lymphoma by Bron, Dominique, Aurer, Igor, André, Marc P E, Bonnet, Christophe, Caballero, Dolores, Falandry, Claire, Kimby, Eva, Soubeyran, Pierre, Zucca, Emanuele, Bosly, Andre, Coiffier, Bertrand

Get full text

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma by Tilly, H, Morschhauser, F, Salles, G, Casasnovas, R-O, Feugier, P, Molina, T J, Jardin, F, Terriou, L, Haioun, C, Coiffier, B

Get full text

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) by Ketterer, N., Coiffier, B., Thieblemont, C., Fermé, C., Brière, J., Casasnovas, O., Bologna, S., Christian, B., Connerotte, T., Récher, C., Bordessoule, D., Fruchart, C., Delarue, R., Bonnet, C., Morschhauser, F., Anglaret, B., Soussain, C., Fabiani, B., Tilly, H., Haioun, C.

“…The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide,…”
Get full text

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab by Feugier, P., Virion, J. M., Tilly, H., Haioun, C., Marit, G., Macro, M., Bordessoule, D., Recher, C., Blanc, M., Molina, T., Lederlin, P., Coiffier, B.

“…Background: The incidence of secondary central nervous system (CNS) occurrences in diffuse large-B-cell lymphoma is not sufficiently high to warrant the use of…”
Get full text

Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma by Haioun, C., Mounier, N., Emile, J.F., Ranta, D., Coiffier, B., Tilly, H., Récher, C., Fermé, C., Gabarre, J., Herbrecht, R., Morchhauser, F., Gisselbrecht, C.

“…This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and…”
Get full text

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma : A multicenter phase II study by COIFFIER, B, HAIOUN, C, CAPDEVILLE, R, DIEHL, V, REYES, F, KETTERER, N, ENGERT, A, TILLY, H, MA, D, JOHNSON, P, LISTER, A, BUSKE, M. F, RADFORD, J. A

“…Rituximab, a chimeric monoclonal antibody that binds specifically to the CD20 antigen, induced objective responses in 50% of patients with low-grade or…”
Get full text

A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases by Traverse-Glehen, A, Felman, P, Callet-Bauchu, E, Gazzo, S, Baseggio, L, Bryon, P A, Thieblemont, C, Coiffier, B, Salles, G, Berger, F

“…Aims : To report the clinicopathological findings of 21 cases of primary nodal marginal zone B‐cell lymphoma (NMZL). NMZL is a recently characterized lymphoma…”
Get full text